Related Experiment Video
Updated: Jun 1, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Alpha-1 antitrypsin gene polymorphism in Chronic Obstructive Pulmonary Disease (COPD)
Sabri Denden1, Amel Haj Khelil, Jalel Knani
1Biochemistry and Molecular Biology Laboratory, Faculty of Pharmacy, Monastir Tunisia.
Genetics and Molecular Biology
|June 4, 2011
Summary
Common Alpha-1-antitrypsin (AAT) gene variations (SERPINA1 polymorphisms) do not appear to increase the risk for developing Chronic Obstructive Pulmonary Disease (COPD) or affect disease progression in emphysema patients.
Area of Science:
- Pulmonary Medicine
- Genetics
- Respiratory Diseases
Background:
- Alpha-1-antitrypsin (AAT) is crucial in preventing emphysema, a key component of Chronic Obstructive Pulmonary Disease (COPD).
- Genetic variations in the SERPINA1 gene, which codes for AAT, are known to affect AAT levels and function.
- The role of common AAT polymorphisms in COPD susceptibility and progression requires further investigation.
Purpose of the Study:
- To investigate the association between common SERPINA1 polymorphisms and the risk of developing COPD.
- To determine if these polymorphisms influence the emphysematous phenotype of COPD.
- To assess the impact of common SERPINA1 polymorphisms on the rate of lung function decline in COPD patients.
Main Methods:
- Case-control study comparing allele frequencies of PiM1, PiM2, PiM3, PiS, and PiZ SERPINA1 alleles in 100 COPD patients and 200 healthy controls.
- Haplotype analysis was performed to examine combinations of alleles.
- A cross-sectional analysis evaluated the relationship between polymorphisms and COPD type, with a two-year follow-up assessing FEV(1) decline.
Main Results:
- No significant differences in allele frequencies or haplotype patterns were found between COPD patients and healthy controls.
- Common SERPINA1 polymorphisms (PiM1, PiM2, PiM3) showed no significant association with the emphysematous type of COPD.
- No significant differences in the annual decline of FEV(1) were observed among carriers of the tested polymorphisms over a two-year period.
Conclusions:
- Common SERPINA1 polymorphisms do not appear to be significant risk factors for developing COPD.
- These genetic variations do not influence the emphysematous phenotype or the rate of lung function decline in COPD patients.
- Further research may be needed to explore rarer SERPINA1 variants or interactions with environmental factors in COPD pathogenesis.
Related Concept Videos
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...